WB, IP, IHC-P, IF-F, IF-IC
H M R Mk
Endogenous
180
Rabbit IgG
#Q6PL18
29028
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunohistochemistry (Paraffin) | 1:50 - 1:200 |
| Immunofluorescence (Frozen) | 1:400 - 1:1600 |
| Immunofluorescence (Immunocytochemistry) | 1:400 - 1:1600 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human ATAD2 protein.
Background
ATPase family AAA domain containing protein 2 (ATAD2) is an oncogenic protein that was originally identified as a coactivator for estrogen receptor (ESR1), and later identified as a coactivator for other transcription factors including c-Myc and E2F1, E2F2, and E2F3 proteins (1-4). ATAD2 is highly expressed and associated with poor prognosis in many types of cancer, including breast, uterine, colon, ovarian, stomach, non-small cell lung carcinoma, osteosarcoma, and cervical cancer (1,5-14). In cancer cells, overexpressed ATAD2 interacts with transcription factors and chromatin modifier proteins to induce the expression of genes that promote cell proliferation and inhibit apoptosis, ultimately promoting tumor growth (15,16). Indeed, knockdown of ATAD2 in pancreatic cancer cell lines has been shown to promote apoptosis, limit cell migration and invasion, and inhibit anchorage-independent growth (17). ATAD2 is a member of the ATPases associated with various cellular activities (AAA) family of proteins and contains a functional AAA domain in its central region, as well as a bromodomain near the C-terminus. The bromodomain binds to acetylated lysine residues on histone proteins, targeting ATAD2 protein to areas of active transcription, where it modulates chromatin structure and recruits additional transcription factors (18,19). Current efforts are underway to better characterize and develop inhibitors to the ATAD2 bromodomain for the treatment of various cancers (16,20-23).
- Zou, J.X. et al. (2007) Proc Natl Acad Sci U S A 104, 18067-72.
- Zou, J.X. et al. (2009) Cancer Res 69, 3339-46.
- Revenko, A.S. et al. (2010) Mol Cell Biol 30, 5260-72.
- Ciró, M. et al. (2009) Cancer Res 69, 8491-8.
- Wang, Y. et al. Lancet 365, 671-9.
- Teschendorff, A.E. et al. (2006) Genome Biol 7, R101.
- Fellenberg, J. et al. (2007) Mod Pathol 20, 1085-94.
- Petroziello, J. et al. (2004) Oncogene 23, 7734-45.
- De Angelis, P.M. et al. (2006) Mol Cancer 5, 20.
- Zheng, L. et al. (2015) Oncol Rep 33, 2337-44.
- Fouret, R. et al. (2012) Clin Cancer Res 18, 5606-16.
- Wan, W.N. et al. (2014) Asian Pac J Cancer Prev 15, 2777-83.
- Wu, G. et al. (2014) BMC Cancer 14, 107.
- Zhang, M. et al. (2016) Clin Transl Oncol 18, 776-81.
- Caron, C. et al. (2010) Oncogene 29, 5171-81.
- Boussouar, F. et al. (2013) Biochim Biophys Acta 1829, 1010-4.
- Liu, N. et al. (2019) Oncol Lett 17, 3489-94.
- Morozumi, Y. et al. (2016) J Mol Cell Biol 8, 349-62.
- Koo, S.J. et al. (2016) Oncotarget 7, 70323-35.
- Gay, J.C. et al. (2019) Proteins 87, 157-67.
- Hussain, M. et al. (2018) Expert Opin Ther Targets 22, 85-96.
- Bamborough, P. et al. (2018) J Med Chem 61, 8321-36.
- Zhou, Y. et al. (2018) Phys Chem Chem Phys 20, 23222-32.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IHC-P: Immunohistochemistry (Paraffin) IF-F: Immunofluorescence (Frozen) IF-IC: Immunofluorescence (Immunocytochemistry)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
